BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A…
$XBI So far, the $145+ support zone has held. Remember this moment a few months from now when, in hindsight, investors say they should have taken advantage of the buying opportunities across the biotech sector. ⬇️⬇️ I have been slowly buying in $BBIO $VKTX $CYTK $PCVX $SLDB…
$BBIO strong support zone for a bounce https://t.co/35SNricyZq
@Pharmdca Adding more $BBIO slowly
$BBIO Nice pullback opportunity https://t.co/2QwXcJf2C2
Biotech names I have been selectively buying on this pullback (seasonality) and because of pullback due to rising yields- $VKTX $BBIO $ABVX $CYTK $AVR $TNGX $ERAS $PCVX $KURA $CRVS $INBX $CELC Few names on my watch list: $AXSM $CTMX $LRMR $MDGL
$BBIO opportunity https://t.co/PJjQtdI327
22 analysts rate BBIO Buy on consensus.
Consensus price target: $107.82 (+60.09% upside from $67.35)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kumar Neil director, Chief Executive Officer | Aug 19, 2026 | Sale | 100 | $8.57K |
| Kumar Neil director, Chief Executive Officer | Aug 19, 2026 | Sale | 8,100 | $679.26K |
| Kumar Neil director, Chief Executive Officer | Aug 19, 2026 | Sale | 1,800 | $152.44K |
| Kumar Neil director, Chief Executive Officer | Aug 18, 2026 | Sale | 14,602 | $1.21M |
| Kumar Neil director, Chief Executive Officer | Aug 18, 2026 | Sale | 1,900 | $154.18K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $502.08M | +126.26% | $-729.31M |
| 2024 | $221.9M | +2285.27% | $-535.76M |
| 2023 | $9.3M | -88.02% | $-643.2M |
Stock data for BBIO: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics